Provisional Program for Advances in NMR on Small Amounts of Mater ial

From: <Michael.Bernstein_at_astrazeneca.com>
Date: Mon, 24 Nov 2003 10:24:33 +0100

Provisional Program for Advances in NMR on Small Amounts of Material

Thursday 26th Feb 2004

AstraZeneca R&D Charnwood, Loughborough, UK




9.45 Coffee

10.20 Introduction and Welcome (Mike Bernstein, AstraZeneca)


Session 1 Introduction to the Techniques:
Chair: Richard Lewis (AstraZeneca)


10.30 TBA (Pfizer, Sandwich)
Title TBA (LC-NMR/MS using cold flow-probes)

10.45 TBA (GSK)
LC-SPE-NMR, separating the Chromatography from the NMR

11.00 Dave Russell (Pfizer, Kalamazoo)
Title TBA (cold probes using tubes)

11.15 Ian Jones (AstraZeneca R&D Macclesfield)
Experience with the 1mm probe in a pharmaceutical development environment

11.30 Chris Sleigh (AstraZeneca R&D Charnwood)
Evaluation of a CapNMR and CapLCNMR system.

11.45 Paul Tan (Lilly)
Title TBA (aspects of automated sample preparation)



12.00 Buffet Lunch
 
Session 2 A Glimpse of the Future
Chair: Martin Sandvoss (GSK)


1.00 Klaus Albert (Institut für Organische Chemie, Universitat Tubingen,
Germany)
        LC-NMR - Present Status and Future

1.30 Lorn Clancey (Protasis)
Dynamic Field Gradient Focusing: A new separation engine for NMR

1.50 TBA (Bruker)
        Title TBA

2.10 TBA (Varian)
        Title TBA


2.30 Coffee


Session 3 Industry Workflow - how can we make these technologies work
in a high-throughput environment?
Chair: Adrian Davis (Pfizer)


3.00 TBA


3.25 Russell Mortishire-Smith (Merck Sharp and Dohme)
Title TBA (Workflow issues in Biological and Metabolite work)

3.50 Gary Sharman (AstraZeneca R&D Macclesfield)
Title TBA (Workflow issues in a Chemical Development Laboratory)


4.15 Discussion
        Chair: Duncan Farrant (GSK)

4.45 Closing Remarks

Followed by informal discussion.
  
Registration

Although there is no meeting fee, registration in advance is essential. It
will not be possible to register or just turn up on the day. The number of
delegates is limited (though expected to be sufficient) and early
registration is advised.

Registration is by email to Helen George (Helen.M.George_at_AstraZeneca.com),
and should include the subject "NMRDG Meeting" and the following
information:

Name:
Affiliation: (university, company etc)
Contact address and phone number:
Contact email:
Dietary requirements (if any)

Registration closes on 30th January 2004.


Cancellation

In order to avoid wasted food, and to allow others to attend if the meeting
is over subscribed, those who are registered for the meeting, but who later
find that they are unable to attend, will be required to cancel their
registration. It will be possible to cancel until 1 week before the
meeting.


Location and Accommodation

Loughborough is located between Leicester, Nottingham and Derby just off J23
of the M1, and AstraZeneca R&D Charnwood is located on the north side of the
town. A map of the location can be found at www.multimap.com using the
postcode LE11 5RH, or alternatively directions can be sent if you contact
Helen George on the email address above.

Accommodation is available at the Ramada Jarvis Hotel, High St.
Loughborough, (tel 01509 214893), at special rates (quote "AstraZeneca") for
B&B of £79.50/£89.50. The hotel is approximately 2 miles from the site.

No accommodation has been reserved, and should accommodation be required,
delegates are responsible for making their own reservations and payments to
the hotel.

There is other accommodation available in the town.


Further Information

Further information about the program may be obtained from Richard Lewis
(Richard.J.Lewis_at_AstraZeneca.com; Department of Physical and Metabolic
Science, AstraZeneca R&D Charnwood, Bakewell Road, Loughborough, Leics. LE11
5RH. Phone: 01509 644062).

Information about registration, accommodation, location etc should be
addressed to Helen George (email address above).


Meeting Organisers and Sponsorship

The meeting has been organised on behalf of the NMRDG by Richard Lewis,
Adrian Davis and Martin Sandvoss.

The organisers wish to thank GlaxoSmithKline and AstraZeneca for sponsorship
of the meeting.
Received on Mon Nov 24 2003 - 08:27:52 MST

This archive was generated by hypermail 2.4.0 : Wed Jun 07 2023 - 17:14:43 MST